The magazine specialized in health issues, The Lancet, published an article on a study by the Ministry of Health of the Province of Buenos Aires entitled “Effectiveness of homologous and heterologous boosters after primary schemes with Sputnik V, Astra-Zeneca and Sinopharm during the Ómicron period in adults over 50 years of age in Argentina.”
The study was carried out on the registry of 422,144 people who were tested in the province of Buenos Aires during the outbreak of the Ómicron variant. In this context, it was found that the combination of booster vaccines (mRNA and viral vector) could provide greater protection against the risk of death from COVID. Additionally, this combination could last longer in people over 50 years of age.
“These articles show the importance of analysis, monitoring and research of records, which allow appropriate decisions to be made to improve the health of the population,” said the Minister of Health of the Province of Buenos Aires, Nicolás Kreplak, one of the authors of the study. .
Strictly speaking, the study indicates that “the administration of heterologous boosters could provide greater protection and a longer duration of effect against COVID-19-related deaths in people over 50 years of age compared to homologous boosters, during the predominance of omicrons. . “The inactivated vaccine schedule followed by a viral vector booster seemed to be associated with the best protection against death.”
Verónica González, director of research and technical cooperation of the PBA Ministry of Health, explained that “several conclusions were reached from the analysis of databases of these 422,144 adults over 50 years of age who have been tested during the outbreak. of the Ómicron variant, in which it is shown that the vaccines are 72% effective in prevention and hospitalizations and 75% against death.” And he added that “however, when the analysis of the different combinations is carried out, the conclusion is reached that when we talk about heterologous reinforcements, of schemes that are based on different technologies, there is greater and much more lasting protection, compared to “the reinforcements applied when the same technology as the initial scheme is used.”
The undersecretary of the Undersecretary of Information Management, Permanent Education and Supervision of the Ministry of Health of Buenos Aires, Leticia Ceriani, also participated in the study; the director of Epidemiology, Teresa Varela, the head of Advisors of the health portfolio, Enio García and Soledad González, advisor to the Ministry of Health of the PBA, other officials of that portfolio.
#Lancet #published #Buenos #Aires #study #vaccine #combination #Province #Buenos #Aires #Province #Buenos #Aires